NDAORALTABLET
Approved
Jan 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
2
Data completeness
4/8 — Partial
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SAVAYSA (edoxaban tosylate) is an oral Factor Xa inhibitor anticoagulant approved in 2015 for stroke prevention and thromboembolic disease. It is a small-molecule direct oral anticoagulant (DOAC) that inhibits Factor Xa, a key enzyme in the coagulation cascade. The drug is administered as an oral tablet with flexible dosing based on patient factors.
$0.005BPart D
LOE Approaching1.5 years to LOEThe product is approaching loss of exclusivity with minimal current Part D spending, indicating a mature or contracted market position requiring defensive strategies and potential portfolio transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Started Oct 2009
8,292 enrolled
Venous ThromboembolismDeep Vein Thrombosis (DVT)Pulmonary Embolism (PE)+2 more
A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation
Started Jun 2007
1,146 enrolled
Atrial FibrillationThromboembolism
Why This Matters for Your Career
Worked on SAVAYSA at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.